Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARC R HAPPE

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1164580874
CMS profile
7095
Location
UNIONTOWN, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$251.43

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $251.43 13

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARC R HAPPE

NPI 1164580874 · CMS profile ID 7095

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

UNIONTOWN, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164580874?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARC R HAPPE, NPI 1164580874, CMS profile ID 7095. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164580874?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARC R HAPPE, NPI 1164580874, CMS profile ID 7095. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164580874?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARC R HAPPE, NPI 1164580874, CMS profile ID 7095, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1164580874?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $251.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $20.1412/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794745287 CMS
Janssen Biotech, Inc. $18.0408/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787945833 CMS
AbbVie Inc. $17.1408/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794745283 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.0407/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850271411 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.3407/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850104137 CMS
Janssen Biotech, Inc. $15.0306/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787945837 CMS
AbbVie Inc. $16.5806/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794745279 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.8306/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850031027 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.5906/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849981695 CMS
AbbVie Inc. $12.4205/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794745275 CMS
Janssen Biotech, Inc. $14.2305/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787945835 CMS
Medtronic, Inc. $42.0205/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815782003 CMS
AbbVie Inc. $13.0303/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794745271 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $290.88 11
PY2020 $2,661.03 6
PY2021 $251.43 13
PY2022 $608.39 35
PY2023 $453.67 27
PY2024 $940.57 50
PY2025 $590.66 32

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $300,840.48 113
PY2024 Principal investigator $6,773.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

113 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bausch Health US, LLC $350.00 12/18/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840593
Principal investigator 1 Bausch Health US, LLC $1,500.00 12/18/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840604
Principal investigator 1 Bausch Health US, LLC $1,500.00 12/18/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840624
Principal investigator 1 Bausch Health US, LLC $1,500.00 12/18/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840644
Principal investigator 1 Bausch Health US, LLC $800.00 12/18/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840648
Principal investigator 1 Bausch Health US, LLC $168.00 12/18/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840651
Principal investigator 1 Janssen Research & Development, LLC $3,650.00 12/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175412422
Principal investigator 1 F. Hoffmann-La Roche AG $182.00 12/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607375
Principal investigator 1 F. Hoffmann-La Roche AG $3,298.00 12/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607379
Principal investigator 1 F. Hoffmann-La Roche AG $1,144.00 12/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607383
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 12/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607388
Principal investigator 1 F. Hoffmann-La Roche AG $129.00 12/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607392
Principal investigator 1 F. Hoffmann-La Roche AG $8,939.00 12/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607395
Principal investigator 1 Genentech, Inc. $714.00 12/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607730
Principal investigator 1 Genentech, Inc. $258.00 12/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607738
Principal investigator 1 Genentech, Inc. $19,746.00 12/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607741
Principal investigator 1 Genentech, Inc. $3,682.00 12/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607746
Principal investigator 1 Genentech, Inc. $9,830.00 12/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607735
Principal investigator 1 Genentech, Inc. $179.00 11/14/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607718
Principal investigator 1 Genentech, Inc. $3,682.00 11/14/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607722
Principal investigator 1 Genentech, Inc. $280.00 11/14/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607728
Principal investigator 1 Bausch Health US, LLC $504.00 11/12/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840613
Principal investigator 1 Bausch Health US, LLC $500.00 11/12/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840616
Principal investigator 1 Bausch Health US, LLC $728.00 11/12/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840628
Principal investigator 1 Bausch Health US, LLC $1,050.00 11/12/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840636
Principal investigator 1 Bausch Health US, LLC $1,483.00 11/06/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840596
Principal investigator 1 Bausch Health US, LLC $1,483.00 11/06/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840601
Principal investigator 1 Bausch Health US, LLC $1,414.00 11/06/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840609
Principal investigator 1 Bausch Health US, LLC $1,483.00 11/06/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840631
Principal investigator 1 Janssen Research & Development, LLC $1,825.00 10/23/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175412418
Principal investigator 1 Bausch Health US, LLC $2,464.00 10/06/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840620
Principal investigator 1 Bausch Health US, LLC $2,464.00 10/06/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840640
Principal investigator 1 Janssen Research & Development, LLC $277.00 09/26/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175412449
Principal investigator 1 Janssen Research & Development, LLC $1,975.00 09/22/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175412453
Principal investigator 1 Bausch Health US, LLC $350.00 09/19/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840498
Principal investigator 1 Bausch Health US, LLC $1,000.00 09/19/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840512
Principal investigator 1 F. Hoffmann-La Roche AG $2,389.89 09/18/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607357
Principal investigator 1 Genentech, Inc. $3,270.00 09/18/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607642
Principal investigator 1 F. Hoffmann-La Roche AG $1,090.00 09/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607331
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 09/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607344
Principal investigator 1 F. Hoffmann-La Roche AG $141.00 09/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607360
Principal investigator 1 F. Hoffmann-La Roche AG $1,090.00 09/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607368
Principal investigator 1 Genentech, Inc. $1,090.00 09/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607638
Principal investigator 1 Bausch Health US, LLC $1,835.00 09/03/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840444
Principal investigator 1 Bausch Health US, LLC $1,835.00 09/03/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840452
Principal investigator 1 Bausch Health US, LLC $1,835.00 09/03/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840480
Principal investigator 1 Bausch Health US, LLC $461.00 09/03/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840494
Principal investigator 1 Bausch Health US, LLC $1,414.00 09/03/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840502
Principal investigator 1 Genentech, Inc. $10,132.00 09/03/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607662
Principal investigator 1 Janssen Research & Development, LLC $1,825.00 08/20/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175412443
Principal investigator 1 F. Hoffmann-La Roche AG $654.00 07/31/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607317
Principal investigator 1 F. Hoffmann-La Roche AG $9,219.00 07/31/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607326
Principal investigator 1 F. Hoffmann-La Roche AG $339.00 07/31/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607352
Principal investigator 1 F. Hoffmann-La Roche AG $3,298.00 07/31/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607365
Principal investigator 1 AstraZeneca UK Limited $53,250.50 07/30/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH, LLC
A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe Crohns Disease AMALTHEA No dispute reported 06/30/2026 1185549671
Principal investigator 1 Bausch Health US, LLC $182.00 07/25/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840476
Principal investigator 1 Bausch Health US, LLC $336.00 07/25/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840488
Principal investigator 1 Bausch Health US, LLC $1,400.00 07/25/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840520
Principal investigator 1 Janssen Research & Development, LLC $1,825.00 07/24/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175412428
Principal investigator 1 Bausch Health US, LLC $461.00 07/23/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840473
Principal investigator 1 Bausch Health US, LLC $461.00 07/23/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840524
Principal investigator 1 Bausch Health US, LLC $461.00 07/07/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840448
Principal investigator 1 Bausch Health US, LLC $1,781.00 07/07/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840461
Principal investigator 1 Bausch Health US, LLC $1,718.00 07/07/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840467
Principal investigator 1 Bausch Health US, LLC $1,718.00 07/07/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840485
Principal investigator 1 Bausch Health US, LLC $1,414.00 07/07/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840490
Principal investigator 1 Bausch Health US, LLC $1,718.00 07/07/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840508
Principal investigator 1 F. Hoffmann-La Roche AG $1,500.00 07/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607322
Principal investigator 1 F. Hoffmann-La Roche AG $3,048.09 07/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607335
Principal investigator 1 F. Hoffmann-La Roche AG $1,250.00 07/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607340
Principal investigator 1 F. Hoffmann-La Roche AG $11,000.00 07/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607348
Principal investigator 1 F. Hoffmann-La Roche AG $1,500.00 07/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211607371
Principal investigator 1 Bausch Health US, LLC $273.00 07/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840457
Principal investigator 1 Bausch Health US, LLC $168.00 07/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840470
Principal investigator 1 Bausch Health US, LLC $1,250.00 07/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840483
Principal investigator 1 Bausch Health US, LLC $2,000.00 07/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840504
Principal investigator 1 Bausch Health US, LLC $700.00 07/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840516
Principal investigator 1 Genentech, Inc. $10,332.00 07/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607654
Principal investigator 1 Genentech, Inc. $10,384.00 07/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607669
Principal investigator 1 Janssen Research & Development, LLC $1,825.00 06/20/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175412407
Principal investigator 1 Genentech, Inc. $436.00 06/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607521
Principal investigator 1 Genentech, Inc. $3,682.00 06/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607525
Principal investigator 1 Genentech, Inc. $182.00 06/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607534
Principal investigator 1 Genentech, Inc. $8,939.00 06/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607542
Principal investigator 1 Genentech, Inc. $280.00 06/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607547
Principal investigator 1 Genentech, Inc. $129.00 06/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607551
Principal investigator 1 Bausch Health US, LLC $461.00 06/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840532
Principal investigator 1 Bausch Health US, LLC $461.00 06/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840551
Principal investigator 1 Bausch Health US, LLC $461.00 06/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840558
Principal investigator 1 Bausch Health US, LLC $1,781.00 06/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840573
Principal investigator 1 Bausch Health US, LLC $461.00 06/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840588
Principal investigator 1 Janssen Research & Development, LLC $4,402.00 05/23/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175412439
Principal investigator 1 Bausch Health US, LLC $700.00 05/21/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840528
Principal investigator 1 Bausch Health US, LLC $252.00 05/21/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840580
Principal investigator 1 Bausch Health US, LLC $1,781.00 05/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840591
Principal investigator 1 Genentech, Inc. $1,500.00 05/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607517
Principal investigator 1 Genentech, Inc. $11,000.00 05/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607530
Principal investigator 1 Genentech, Inc. $1,250.00 05/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607538
Principal investigator 1 Genentech, Inc. $3,000.00 05/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607554
Principal investigator 1 Genentech, Inc. $5,500.00 04/22/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211607513
Principal investigator 1 Janssen Research & Development, LLC $1,729.00 04/17/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175412394
Principal investigator 1 Janssen Research & Development, LLC $4,275.00 04/17/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175412400
Principal investigator 1 Bausch Health US, LLC $637.00 04/11/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840554
Principal investigator 1 Bausch Health US, LLC $700.00 04/11/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840577
Principal investigator 1 Bausch Health US, LLC $461.00 04/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840537
Principal investigator 1 Bausch Health US, LLC $75.00 04/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840541
Principal investigator 1 Bausch Health US, LLC $262.00 04/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840544
Principal investigator 1 Bausch Health US, LLC $262.00 04/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840549
Principal investigator 1 Bausch Health US, LLC $819.00 04/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840563
Principal investigator 1 Bausch Health US, LLC $1,000.00 04/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840569
Principal investigator 1 Bausch Health US, LLC $262.00 04/02/2025 Non-covered Recipient Entity
Frontier Clinical Research, LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224840584
Principal investigator 1 Janssen Research & Development, LLC $1,948.00 03/27/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175412434
Principal investigator 1 Janssen Research & Development, LLC $6,748.00 01/20/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175412412